Cargando…
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
Targeted therapy and immunotherapy have revolutionized treatment of various cancers in the past decade. Despite targeted therapy with trastuzumab in Her2-positive gastric cancer patients, survival has been dismal, mostly due to disease progression and toxicity related to the treatments. One area of...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427576/ https://www.ncbi.nlm.nih.gov/pubmed/28494772 http://dx.doi.org/10.1186/s13045-017-0473-4 |